Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR2 | P25025 | 8/20 | 0.67 |
| ▸ | MEN1 | O00255 | 3/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.65 |
| ▸ | SCN9A | Q15858 | 6/20 | 0.60 |
| ▸ | LMNA | P02545 | 3/20 | 0.57 |
| ▸ | USP2 | O75604 | 1/20 | 0.57 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.51 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL489686 | 0.88 | MEN1 (0.77) | CXCR2MEN1KMT2ASCN9ALMNA | |
| SCHEMBL489952 | 0.80 | MEN1 (0.81) | MEN1KMT2ASCN9ALMNAUSP2 | |
| SCHEMBL3853163 | 0.76 | RAB9A (0.57) | CXCR2MEN1KMT2A | |
| SCHEMBL489784 | 0.76 | SCN9A (0.56) | MEN1KMT2ASCN9ALMNAUSP2 | |
| SCHEMBL4225334 | 0.74 | CXCR2 (1.00) | CXCR2 | |
| SCHEMBL842322 | 0.74 | CXCR2 (0.70) | CXCR2 | |
| SCHEMBL4497818 | 0.73 | CXCR2 (0.61) | CXCR2 | |
| SCHEMBL489736 | 0.73 | KMT2A (1.00) | MEN1KMT2ASCN9ALMNAUSP2 | |
| SCHEMBL5951413 | 0.71 | RAB9A (0.51) | CXCR2 | |
| SCHEMBL490008 | 0.71 | NPC1 (0.48) | CXCR2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1527051-B1 | PYRIMIDYL SULPHONE AMIDE DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS | ASTRAZENECA AB (SE) | 2012-09-12 | — | — | EP | disclosed |
| US-8106063-B2 | Pyrimidyl sulphone amide derivatives as chemokine receptor modulators | ASTRAZENECA AB (SE) | 2012-01-31 | — | — | US | disclosed |
| US-20100063079-A1 | Pyrimidyl Sulphone Amide Derivatives as Chemokine Receptor Modulators | ASTRAZENECA AB (SE) | 2010-03-11 | — | — | US | disclosed |
| US-7585867-B2 | Substituted thiazolo[4,5-d]pyrimidin-2(3H)-one | ASTRAZENECA AB (SE) | 2009-09-08 | — | — | US | disclosed |
| US-7585867-B2 | Substituted thiazolo[4,5-d]pyrimidin-2(3H)-one | ASTRAZENECA AB (SE) | 2009-09-08 | — | — | US | disclosed |
| US-7585867-B2 | Substituted thiazolo[4,5-d]pyrimidin-2(3H)-one | ASTRAZENECA AB (SE) | 2009-09-08 | — | — | US | disclosed |
| EP-1543013-B1 | 5-[[(2,3-Difluorophenyl)methyl]thio]-7-[[2-hydroxy-1-(hydroxymethyl)-1-methylethyl]amino]thiazolo[4,5-d]pyrimidin-2(3H)-one monosodium salt as CXCR2 antagonist | ASTRAZENECA AB (SE) | 2008-12-31 | — | — | EP | disclosed |
| EP-1543013-B1 | 5-[[(2,3-Difluorophenyl)methyl]thio]-7-[[2-hydroxy-1-(hydroxymethyl)-1-methylethyl]amino]thiazolo[4,5-d]pyrimidin-2(3H)-one monosodium salt as CXCR2 antagonist | ASTRAZENECA AB (SE) | 2008-12-31 | — | — | EP | disclosed |
| EP-1542974-B1 | 5-[((2,3-difluorophenyl)methyl)thio]-7-{[(1S,2S)-2-hydroxy-1-(hydroxymethyl)propyl]amino}thiazolo[4,5-d]pyrimidin-2(3H)-one as CXCR2 antagonist | ASTRAZENECA AB (SE) | 2008-12-31 | — | — | EP | disclosed |
| EP-1542974-B1 | 5-[((2,3-difluorophenyl)methyl)thio]-7-{[(1S,2S)-2-hydroxy-1-(hydroxymethyl)propyl]amino}thiazolo[4,5-d]pyrimidin-2(3H)-one as CXCR2 antagonist | ASTRAZENECA AB (SE) | 2008-12-31 | — | — | EP | disclosed |
| US-20080306262-A1 | Novel Compound | ASTRAZENECA AB, A SWEDISH CORPORATION | 2008-12-11 | — | — | US | disclosed |
| US-20080306262-A1 | Novel Compound | ASTRAZENECA AB, A SWEDISH CORPORATION | 2008-12-11 | — | — | US | disclosed |
| US-20080306262-A1 | Novel Compound | ASTRAZENECA AB, A SWEDISH CORPORATION | 2008-12-11 | — | — | US | disclosed |
| US-20060100221-A1 | Novel compound | ASTRAZENECA AB (SE) | 2006-05-11 | — | — | US | disclosed |
| US-20050272750-A1 | Novel compound | ASTRAZENECA AB (SE) | 2005-12-08 | — | — | US | disclosed |
| EP-1527051-A1 | PYRIMIDYL SULPHONE AMIDE DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS | Astrazeneca AB (SE) | 2005-05-04 | — | — | EP | disclosed |
| WO-2004011443-A1 | PYRIMIDYL SULPHONE AMIDE DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS | ASTRAZENECA AB (SE) | 2004-02-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100063079-A1 | Pyrimidyl Sulphone Amide Derivatives as Chemokine Receptor Modulators | ACKR3, GPR17, CCL11 | CXCR2 38/4885MEN1 3586/4885KMT2A 3621/4885 |
| US-20060100221-A1 | Novel compound | SLC10A1, AVPR2, NPC1 | CXCR2 156/4885MEN1 839/4885KMT2A 4421/4885 |
| US-20050272750-A1 | Novel compound | SLC10A1, AVPR2, NPC1 | CXCR2 156/4885MEN1 839/4885KMT2A 4421/4885 |
| US-20080306262-A1 | Novel Compound | SLC10A1, AVPR2, NPC1 | CXCR2 156/4885MEN1 839/4885KMT2A 4421/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.